Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 2000

View Archived Issues

Protein-peptide fusion stimulates anticancer activity without adjuvant

Researchers identify ACE2, the first human homologue of ACE

Eptifibatide reduces death, myocardial infarction in unstable angina

Male osteoporosis treated effectively with alendronate in two-year study

Parkinson's marked by loss of norepinephrine nerve terminals in the heart

New proxifan H3 antagonist selected as development candidate for ADHD and Alzheimer's disease

Novel duocarmycin derivative suitable for use in anticancer immunoconjugates

Toleragen candidate for antibody-mediated thrombosis effective in preclinical model

Oleander extract selectively kills human cancer cells via an effect on TRF2

Rabeprazole superior to ranitidine in erosive gastroesophageal reflux disease

Antibody and protein therapeutics for breast cancer sought by Eos and Biogen collaboration

Update on U.S. status of Zonagen's sexual dysfunction products

Celgene expands product pipeline and technology platform with Signal acquisition

OSI's ERF receptor inhibitor continues to demonstrate anticancer activity and good safety

Important new approval obtained for Actos

Potent hydroxamate-based MMP-2 inhibitors disclosed by Abbott

Serine protease inhibitors for asthma, pancreatitis designed by Ortho-McNeil scientists

Series of patents covers American Cyanamid's new TACE inhibitors

Technetium complexes and their use in cardiac imaging

Novel treatments for obesity under study at Lilly

Pfizer prepares acid-stable, broad-spectrum macrolide antibiotics

HEV vaccine technology licensed to SmithKline Beecham

Encouraging results reported for phenserine in multiple-dose safety trial

Pfizer initiates clinical program for pagoclone

Phase I/II clinical trial demonstrates safety and tolerability of GVAX lung cancer vaccine

New therapy for AIDS wasting receives orphan product designation from E.C.

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026